Kirk Taylor, standout pharma executive, talks, walks diversity baystatebanner.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baystatebanner.com Daily Mail and Mail on Sunday newspapers.
Operator: Greetings, and welcome to the Brainstorm Cell Therapeutics First Quarter 2023 Earnings Call. At this time, participants are in a listen-only mode. As a reminder this call is being recorded.
Share this article
Share this article
BEDMINSTER, N.J., May 4, 2021 /PRNewswire/ Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, recently named Ernesto Aycardi, M.D., to the position of Chief Development Officer on April 26, and is welcoming Eslie Dennis, M.D., MBChB, FCP(SA) in the role of Chief Medical Officer today. These appointments come at a pivotal time for the company, as the North America region aims to realize the full potential of its existing commercial portfolio and compounds being investigated in the pipeline. In particular, the company is working on plans to advance KW-6356, a selective antagonist of adenosine A2A receptors, and KHK4083, an Anti-OX40 Fully Human Antibody, and is also collaborating with partner MEI Pharma to complete the pivotal study and shape a broader development program for zandelisib, a selective PI3Kδ inhibitor.